Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI).


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 28 07 2021
accepted: 27 01 2022
revised: 21 01 2022
pubmed: 9 3 2022
medline: 25 5 2022
entrez: 8 3 2022
Statut: ppublish

Résumé

Breast density is an independent risk factor for the development of breast cancer and also decreases the sensitivity of mammography for screening. Consequently, women with extremely dense breasts face an increased risk of late diagnosis of breast cancer. These women are, therefore, underserved with current mammographic screening programs. The results of recent studies reporting on contrast-enhanced breast MRI as a screening method in women with extremely dense breasts provide compelling evidence that this approach can enable an important reduction in breast cancer mortality for these women and is cost-effective. Because there is now a valid option to improve breast cancer screening, the European Society of Breast Imaging (EUSOBI) recommends that women should be informed about their breast density. EUSOBI thus calls on all providers of mammography screening to share density information with the women being screened. In light of the available evidence, in women aged 50 to 70 years with extremely dense breasts, the EUSOBI now recommends offering screening breast MRI every 2 to 4 years. The EUSOBI acknowledges that it may currently not be possible to offer breast MRI immediately and everywhere and underscores that quality assurance procedures need to be established, but urges radiological societies and policymakers to act on this now. Since the wishes and values of individual women differ, in screening the principles of shared decision-making should be embraced. In particular, women should be counselled on the benefits and risks of mammography and MRI-based screening, so that they are capable of making an informed choice about their preferred screening method. KEY POINTS: • The recommendations in Figure 1 summarize the key points of the manuscript.

Identifiants

pubmed: 35258677
doi: 10.1007/s00330-022-08617-6
pii: 10.1007/s00330-022-08617-6
pmc: PMC9122856
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4036-4045

Informations de copyright

© 2022. The Author(s).

Références

Boyd NF, Guo H, Martin LJ et al (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med. 356(3):227–236
D’Orsi CJ, Sickles EA, Mendelson EB et al (2013) ACR BI-RADS ® Atlas, Breast Imaging Reporting and Data System. American College of Radiology, Reston, VA
Sprague BL, Kerlikowske K, Bowles EJA et al (2019) Trends in clinical breast density assessment from the Breast Cancer Surveillance Consortium. J Natl Cancer Inst 111(6):629–632
Brandt KR, Scott CG, Ma L et al (2016) Comparison of clinical and automated breast density measurements: implications for risk prediction and supplemental screening. Radiology. 279(3):710–719
Jeffers AM, Sieh W, Lipson JA et al (2017) Breast cancer risk and mammographic density assessed with semiautomated and fully automated methods and BI-RADS. Radiology. 282(2):348–355
Astley SM, Harkness EF, Sergeant JC et al (2018) A comparison of five methods of measuring mammographic density: a case-control study. Breast Cancer Res. 20(1):10
McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 15(6):1159–1169
Wanders JOP, van Gils CH, Karssemeijer N et al (2018) The combined effect of mammographic texture and density on breast cancer risk: a cohort study. Breast Cancer Res. 20(1):36
Brentnall AR, Cuzick J, Buist DSM, Bowles EJA (2018) Long-term accuracy of breast cancer risk assessment combining classic risk factors and breast density. JAMA Oncol. 4(9):e180174
Vachon CM, Pankratz VS, Scott CG et al (2015) The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst 107(5):dju397
Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K (2017) Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 3(9):1228–1236
Chiu SY, Duffy S, Yen AM, Tabár L, Smith RA, Chen HH (2010) Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol Biomark Prev 19(5):1219–1228
Heindl F, Fasching PA, Hein A et al (2021) Mammographic density and prognosis in primary breast cancer patients. Breast. 59:51–57
van der Waal D, Verbeek ALM, Broeders MJM (2018) Breast density and breast cancer-specific survival by detection mode. BMC Cancer. 18(1):386
doi: 10.1186/s12885-018-4316-7
World Health Organisation (2006) Guidelines for the early detection and screening of breast cancer. EMRO Technical Publications Series
Sardanelli F, Aase HS, Alvarez M et al (2017) Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey. Eur Radiol 27(7):2737–2743
Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M (2012) The benefits and harms of breast cancer screening: an independent review. Lancet. 380(9855):1778–1786
doi: 10.1016/S0140-6736(12)61611-0
Lauby-Secretan B, Scoccianti C, Loomis D et al (2015) Breast-cancer screening--viewpoint of the IARC Working Group. N Engl J Med 372(24):2353–2358
Paci E, Broeders M, Hofvind S, Puliti D, Duffy SW (2014) European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. Cancer Epidemiol Biomark Prev 23(7):1159–1163
Freer PE (2015) Mammographic breast density: impact on breast cancer risk and implications for screening. Radiographics 35(2):302–315
Wanders JO, Holland K, Veldhuis WB et al (2017) Volumetric breast density affects performance of digital screening mammography. Breast Cancer Res Treat. 162(1):95–103
Østerås BH, Martinsen ACT, Gullien R, Skaane P (2019) Digital mammography versus breast tomosynthesis: impact of breast density on diagnostic performance in population-based screening. Radiology. 293(1):60–68
doi: 10.1148/radiol.2019190425
Conant EF, Barlow WE, Herschorn SD et al (2019) Association of digital breast tomosynthesis vs digital mammography with cancer detection and recall rates by age and breast density. JAMA Oncol 5(5):635–642
Berg WA, Blume JD, Cormack JB et al (2008) Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 299(18):2151–2163
Ohuchi N, Suzuki A, Sobue T et al (2016) Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet. 387(10016):341–348
Vourtsis A, Berg WA (2019) Breast density implications and supplemental screening. Eur Radiol. 29(4):1762–1777
doi: 10.1007/s00330-018-5668-8
Tagliafico AS, Mariscotti G, Valdora F et al (2018) A prospective comparative trial of adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts (ASTOUND-2). Eur J Cancer. 104:39–46
Berg WA, Zhang Z, Lehrer D et al (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 307(13):1394–1404
Evans A, Trimboli RM, Athanasiou A et al (2018) Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Imaging. 9(4):449–461
Gollmer A, Link T, Weissenhofer S (2021): Dritter Evaluationsbericht zum Österreichischen Brustkrebs‐Früherkennungsprogramm. Evaluationsbericht für die Jahre 2014 bis 2019. Gesundheit Österreich, Wien
Bakker MF, de Lange SV, Pijnappel RM et al (2019) Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med. 381(22):2091–2102
Veenhuizen SGA, de Lange SV, Bakker MF et al (2021) Supplemental breast MRI for women with extremely dense breasts: results of the second screening round of the DENSE trial. Radiology. 299(2):278–286
Geuzinge HA, Bakker MF, Heijnsdijk EAM et al (2021) Cost-effectiveness of MRI screening for women with extremely dense breast tissue. J Natl Cancer Inst. 113(11):1476–1483
Comstock CE, Gatsonis C, Newstead GM et al (2020) Comparison of abbreviated breast MRI vs digital breast tomosynthesis for breast cancer detection among women with dense breasts undergoing screening. JAMA. 323(8):746–756
Mann RM, Kuhl CK, Kinkel K, Boetes C (2008) Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 18(7):1307–1318
doi: 10.1007/s00330-008-0863-7
Mann RM, Balleyguier C, Baltzer PA et al (2015) Breast MRI: EUSOBI recommendations for women's information. Eur Radiol 25(12):3669–3678
Behzadi AH, Zhao Y, Farooq Z, Prince MR (2018) Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology. 286(2):471–482
doi: 10.1148/radiol.2017162740
Bick U, Trimboli RM, Athanasiou A et al (2020) Image-guided breast biopsy and localisation: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Imaging 11(1):12
Vilmun BM, Vejborg I, Lynge E et al (2020) Impact of adding breast density to breast cancer risk models: a systematic review. Eur J Radiol 127:109019
Dembower K, Wahlin E, Liu Y et al (2021) Effect of artificial intelligence-based triaging of breast cancer screening mammograms on cancer detection and radiologist workload: a retrospective simulation study - the Lancet Digital Health. Lancet Digit Health 2(9):E468–EE74
Mann RM, Hooley R, Barr RG, Moy L (2020) Novel approaches to screening for breast cancer. Radiology. 297(2):266–285
doi: 10.1148/radiol.2020200172

Auteurs

Ritse M Mann (RM)

Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, Netherlands. ritse.mann@radboudumc.nl.
The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands. ritse.mann@radboudumc.nl.

Alexandra Athanasiou (A)

Breast Imaging Department, MITERA Hospital, 6, Erithrou Stavrou Str. 151 23 Marousi, Athens, Greece.

Pascal A T Baltzer (PAT)

Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Research Group: Molecular and Gender Imaging, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Wien, Austria.

Julia Camps-Herrero (J)

Hospitales Ribera Salud, Avda.Cortes Valencianas, 58, 46015, Valencia, Spain.

Paola Clauser (P)

Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Research Group: Molecular and Gender Imaging, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Wien, Austria.

Eva M Fallenberg (EM)

Department of Diagnostic and Interventional Radiology, School of Medicine &; Klinikum Rechts der Isar, Technical University of Munich, Munich (TUM), Ismaninger Str. 22, 81675, München, Germany.

Gabor Forrai (G)

Department of Radiology, Duna Medical Center, Budapest, Hungary.

Michael H Fuchsjäger (MH)

Division of General Radiology, Department of Radiology, Medical University Graz, Auenbruggerplatz 9, 8036, Graz, Austria.

Thomas H Helbich (TH)

Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Research Group: Molecular and Gender Imaging, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Wien, Austria.

Fleur Killburn-Toppin (F)

Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Hills road, Cambridge, CB20QQ, UK.

Mihai Lesaru (M)

Radiology and Imaging Laboratory, Carol Davila University, Bucharest, Romania.

Pietro Panizza (P)

Breast Imaging Unit, IRCCS Ospedale San Raffaele,, Via Olgettina 60, 20132, Milan, Italy.

Federica Pediconi (F)

Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy.

Ruud M Pijnappel (RM)

Department of Imaging, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, Netherlands.
Dutch Expert Centre for Screening (LRCB), Wijchenseweg 101, 6538 SW, Nijmegen, Netherlands.

Katja Pinker (K)

Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Research Group: Molecular and Gender Imaging, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Wien, Austria.
Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, USA.

Francesco Sardanelli (F)

Unit of Radiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Morandi 30, 20097 San Donato Milanese, Milan, Italy.

Tamar Sella (T)

Department of Diagnostic Imaging, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Isabelle Thomassin-Naggara (I)

Department of Radiology, Sorbonne Université, APHP, Hôpital Tenon, 4, rue de la Chine, 75020, Paris, France.

Sophia Zackrisson (S)

Diagnostic Radiology, Department of Translational Medicine, Faculty of Medicine, Lund University, Skåne University Hospital Malmö, SE-205 02, Malmö, Sweden.

Fiona J Gilbert (FJ)

Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Hills road, Cambridge, CB20QQ, UK.

Christiane K Kuhl (CK)

University Hospital of Aachen, Rheinisch-Westfälische Technische Hochschule, Pauwelsstraße30, 52074, Aachen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH